During the last ~10 years, a generation of molecules with agonism at the glucagon-like peptide-1 (GLP-1) receptor have emerged as promising tools in the pharmacotherapy of obesity (106–108). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.